



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 18, 2003

Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thorpe and Ran

Serial No.: 09/998,833

Filed: November 30, 2001

For: COMBINED CANCER TREATMENT
METHODS USING ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Bansal, G.

Atty. Dkt. No.: 4001.002299

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application of the present case. The listed documents were brought to the attention of Applicants' undersigned representative on or about July 08, 2003, which date is less than three months ago. Applicants' undersigned representative was advised of the listed documents by patent counsel to the licensee of the present application, which was said to have arisen as a result of counseling the licensee regarding business matters. The listed documents are being made of record within three months of the pertinent teleconference held on or about July 08, 2003.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002299.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: September 18, 2003

Form PTO-1449 (modified)

Atty. Docket No.
4001.002299Serial No.
09/998,833

List of Patents and Publications for Applicant's

Applicant
Philip E. Thorpe and Sophia Ran

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
November 30, 2001Group:
1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1 and 2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C70	Becker and Brocker, "Antiphospholipid Syndrome Associated with Immunotherapy for Patients with Melanoma," <i>Cancer</i> , 75:2785, 1995
	C71	Bevers <i>et al.</i> , "Changes in Membrane Phospholipid Distribution During Platelet Activation," <i>Biochim. Biophys. Acta.</i> , 122:429-436, 1982.
	C72	Connor <i>et al.</i> , "Exposure of Phosphatidylserine in the Outer Leaflet of Human Red Blood Cells," <i>J. Biol. Chem.</i> , 736:57-66, 1983.
	C73	Fadok <i>et al.</i> , "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages," <i>J. Immunol.</i> , 148:2207-2216, 1992.
	C74	Katsuragawa <i>et al.</i> , "Monoclonal Antiphosphatidylserine Antibody Reactivity Against Human First-Trimester Placental Trophoblasts," <i>Am. J. Obstetr. Gynecol.</i> , 172:1592-1597, 1995.
	C75	Maneta-Peyret <i>et al.</i> , "Demonstration that Anti-Phospholipid Auto-Antibodies React with Both Anionic and Zwitterionic Phospholipids," <i>Immunol. Lett.</i> , 35:141-146, 1993.
	C76	Naldi <i>et al.</i> , "Antiphospholipid Antibodies and Melanoma: A Link?," <i>Dermatology</i> , 184:156, 1992.
	C77	Rote <i>et al.</i> , "Expression of Phosphatidylserine-Dependent Antigens on the Surface of Differentiating BeWo Human Choriocarcinoma Cells," <i>Am. J. Rep. Immunol.</i> , 33:114-121, 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
4001.002299Serial No.
09/998,833

List of Patents and Publications for Applicant's

Applicant
Philip E. Thorpe and Sophia Ran

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
November 30, 2001Group:
1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1 and 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C78	Zwaal and Schroit, "Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells," <i>Blood</i> , 89:1121-1132, 1997.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)